Cullinan Therapeutics, Inc. (CGEM) Q1 2026 Earnings
CGEM·Reported May 7, 2026·Before market open
Diluted EPS came in at $-0.75 (-1.4% YoY), beat the $-0.84 consensus by $0.09.
Diluted EPS
$-0.75beat by $0.09
Consensus: $-0.84
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Cullinan Therapeutics, Inc.'s Q1 2026 earnings report.
Cullinan Therapeutics, Inc. (CGEM) reported Q1 2026 earnings on May 7, 2026 before market open.
Cullinan Therapeutics, Inc. reported diluted EPS of $-0.75 for Q1 2026.
EPS beat the consensus estimate of $-0.84 by $0.09.
Compared to the same quarter a year prior, diluted EPS declined 1.4% from $-0.74.
You can read the 8-K earnings release (0001193125-26-210290) and the 10-Q periodic report (0001193125-26-210304) directly on SEC EDGAR. The filing index links above go to sec.gov.